Alzheimer's disease (AD) is a common neurodegenerative disease, where neuroinflammation significantly influences its pathophysiology by driving the disease's pathological cascade. As a pro-inflammatory regulator, miR-125b-5p contributes to AD progression, though its precise role and mechanisms remain unclear.
Objective
We aims to identify mRNAs significantly regulated by pro-inflammatory miR-125b-5p in AD and uncover key neuroinflammatory pathways.
Methods
Target mRNAs regulated by miR-125b-5p were predicted using online databases and analyzed with two mRNA datasets to identify differentially expressed mRNAs (DEmRNAs). Enrichment analysis was conducted to explore their biological functions and pathways. The significance of DEmRNAs expression in AD-related inflammatory pathways was verified by the Wilcoxon test, predictive accuracy was assessed via area under the curves (AUCs), and novel mRNAs were identified through positive control analysis.
Results
A total of 613 miR-125b-5p target mRNAs were identified, and 44 DEmRNAs were detected to be regulated by miR-125b-5p in two datasets. The 44 target DEmRNAs associated with AD include three key pathways: insulin signaling (EXOC7, FLOT2, MKNK2), phosphatidylinositol signaling (IP6K1, MTMR3), and phospholipase D signaling (CYTH1, GAB2). Correlation analysis indicated strong correlations among 7 mRNAs, all showing significant differential expression, with AUCs above 0.5, confirming their predictive value. Three mRNAs (EXOC7, IP6K1, CYTH1) were identified as novel AD-related genes. MiR-125b-5p binding sites in the 3′-UTRs of these 7 mRNAs suggest their potential roles in AD-related inflammation and signaling pathways.
Conclusions
This study investigates the pro-inflammatory miR-125b-5p's role in the pathological processes of AD, highlighting its regulation of key target mRNAs and critical pathways.
Soria LopezJAGonzálezHMLégerGC. Alzheimer’s disease. Handb Clin Neurol2019; 167: 231–255.
4.
WangJGuBJMastersCL, et al.A systemic view of Alzheimer disease-insights from amyloid-β metabolism beyond the brain. Nat Rev Neurol2017; 13: 612–623.
5.
SiZZZouCJMeiX, et al.Targeting neuroinflammation in Alzheimer’s disease: from mechanisms to clinical applications. Neural Regen Res2022; 18: 708–715.
6.
TanMGChuaWTEsiriMM, et al.Genome wide profiling of altered gene expression in the neocortex of Alzheimer’s disease. J Neurosci Res2010; 88: 1157–1169.
7.
FanCChenKZhouJ, et al.Systematic analysis to identify transcriptome-wide dysregulation of Alzheimer's disease in genes and isoforms. Hum Genet2021; 140: 609–623.
8.
O'BrienJHayderHZayedY, et al.Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne)2018; 9: 402.
9.
JonasSIzaurraldeE. Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet2015; 16: 421–433.
10.
Stevenson-HoareJHeslegraveALeonenkoG, et al.Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer’s disease. Brain2023; 146: 690–699.
11.
ProvostP. Interpretation and applicability of microRNA data to the context of Alzheimer’s and age-related diseases. Aging (Albany NY)2010; 2: 166–169.
12.
AmakiriNKubosumiATranJ, et al.Amyloid beta and microRNAs in Alzheimer’s disease. Front Neurosci2019; 13: 430.
13.
LukiwWJ. Micro-RNA speciation in fetal, adult and Alzheimer’s disease hippocampus. Neuroreport2007; 18: 297–300.
14.
GuedesJRSantanaICunhaC, et al.MicroRNA deregulation and chemotaxis and phagocytosis impairment in Alzheimer’s disease. Alzheimers Dement (Amst)2015; 3: 7–17.
15.
LeMTTehCShyh-ChangN, et al.MicroRNA-125b is a novel negative regulator of p53. Genes Dev2009; 23: 862–876.
16.
PerluigiMBaroneEDi DomenicoF, et al.Aberrant protein phosphorylation in Alzheimer disease brain disturbs pro-survival and cell death pathways. Biochim Biophys Acta2016; 1862: 1871–1882.
17.
QuinlanSKennyAMedinaM, et al.MicroRNAs in neurodegenerative diseases. Int Rev Cell Mol Biol2017; 334: 309–343.
18.
Banzhaf-StrathmannJBenitoEMayS, et al.MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer’s disease. EMBO J2014; 33: 1667–1680.
19.
MaXLiuLMengJ. MicroRNA-125b promotes neurons cell apoptosis and Tau phosphorylation in Alzheimer’s disease. Neurosci Lett2017; 661: 57–62.
20.
HongHLiYSuB.Identification of circulating miR-125b as a potential biomarker of Alzheimer’s disease in APP/PS1 transgenic mouse. J Alzheimers Dis2017; 59: 1449–1458.
21.
VergalloAListaSZhaoY, et al.MiRNA-15b and miRNA-125b are associated with regional Aβ-PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints. Transl Psychiatry2021; 11: 78.
22.
ZhaoYBhattacharjeeSJonesBM, et al.Regulation of neurotropic signaling by the inducible, NF-κB-sensitive miRNA-125b in Alzheimer’s disease (AD) and in primary human neuronal-glial (HNG) cells. Mol Neurobiol2014; 50: 97–106.
23.
AlexandrovPNDuaPHillJM, et al.MicroRNA (miRNA) speciation in Alzheimer’s disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int J Biochem Mol Biol2012; 3: 365–373.
24.
EbrahimiRGolestaniA. The emerging role of noncoding RNAs in neuroinflammation: implications in pathogenesis and therapeutic approaches. J Cell Physiol2022; 237: 1206–1224.
25.
ZhuangJChenZCaiP, et al.Targeting microRNA-125b promotes neurite outgrowth but represses cell apoptosis and inflammation via blocking PTGS2 and CDK5 in a FOXQ1-dependent way in Alzheimer disease. Front Cell Neurosci2020; 14: 587747.
26.
LukiwWJAlexandrovPN. Regulation of complement factor H (CFH) by multiple miRNAs in Alzheimer's disease (AD) brain. Mol Neurobiol2012; 4: 11–19.
27.
LiPXuYWangB, et al.MiR-34a-5p and miR-125b-5p attenuate Aβ-induced neurotoxicity through targeting BACE1. J Neurol Sci2020; 413: 116793.
28.
BazrgarMKhodabakhshPDargahiL, et al.MicroRNA modulation is a potential molecular mechanism for neuroprotective effects of intranasal insulin administration in amyloid βeta oligomer induced Alzheimer's like rat model. Exp Gerontol2022; 164: 111812.
29.
WangSZhouSLiuH, et al.ncRI: a manually curated database for experimentally validated non-coding RNAs in inflammation. BMC Genomics2020; 21: 380.
30.
McGearySELinKSShiCY, et al.The biochemical basis of microRNA targeting efficacy. Science2019; 366: eaav1741.
31.
HuangHYLinYCCuiS, et al.miRTarBase update 2022: an informative resource for experimentally validated miRNA-target interactions. Nucleic Acids Res2022; 50: D222–D230.
32.
LiuWWangX. Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. Genome Biol2019; 20: 18.
33.
ChenYWangX. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res2020; 48: D127–D131.
34.
SoodSGallagherIJLunnonK, et al.A novel multi-tissue RNA diagnostic of healthy ageing relates to cognitive health status. Genome Biol2015; 16: 185.
35.
RitchieMEPhipsonBWuD, et al.Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res2015; 43: e47.
36.
KimesPKLiuYNeil HayesD, et al.Statistical significance for hierarchical clustering. Biometrics2017; 73: 811–821.
37.
YuGWangLGHanY, et al.Clusterprofiler: an R package for comparing biological themes among gene clusters. OMICS2012; 16: 284–287.
38.
LuoWBrouwerC. Pathview: an R/bioconductor package for pathway-based data integration and visualization. Bioinformatics2013; 29: 1830–1831.
39.
DexterF. Wilcoxon-Mann-Whitney test used for data that are not normally distributed. Anesth Analg2013; 117: 537–538.
40.
RobinXTurckNHainardA, et al.pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics2011; 12: 77.
41.
BellenguezCKüçükaliFJansenIE, et al.New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat Genet2022; 54: 412–436.
42.
PiñeroJSaüchJSanzF, et al.The DisGeNET cytoscape app: exploring and visualizing disease genomics data. Comput Struct Biotechnol J2021; 19: 2960–2967.
43.
YuWClyneMKhouryMJ, et al.Phenopedia and genopedia: disease-centered and gene-centered views of the evolving knowledge of human genetic associations. Bioinformatics2010; 26: 145–146.
44.
HuYComjeanAMohrSE, et al.Gene2Function: an integrated online resource for gene function discovery. G3 (Bethesda)2017; 7: 2855–2858.
45.
SchjeideBMHooliBParkinsonM, et al.GAB2 As an Alzheimer disease susceptibility gene: follow-up of genome wide association results. Arch Neurol2009; 66: 250–254.
46.
AngelopoulouEPaudelYNShaikhMF, et al.Flotillin: a promising biomarker for Alzheimer's disease. J Pers Med2020; 10: 20.
47.
AbdullahMKimuraNAkatsuH, et al.Flotillin is a novel diagnostic blood marker of Alzheimer's disease. J Alzheimers Dis2019; 72: 1165–1176.
48.
AlsaqatiMThomasRSKiddEJ. Proteins involved in endocytosis are upregulated by ageing in the normal human brain: implications for the development of Alzheimer’s disease. J Gerontol A Biol Sci Med Sci2018; 73: 289–298.
49.
WangJDaCSuY, et al.MKNK2 Enhances chemoresistance of ovarian cancer by suppressing autophagy via miR-125b. Biochem Biophys Res Commun2021; 556: 31–38.
50.
HaoFItohTMoritaE, et al.The PtdIns3-phosphatase MTMR3 interacts with mTORC1 and suppresses its activity. FEBS Lett2016; 590: 161–173.
51.
LiuYLiuFGrundke-IqbalI, et al.Deficient brain insulin signalling pathway in Alzheimer’s disease and diabetes. J Pathol2011; 225: 54–62.
52.
SędzikowskaASzablewskiL. Insulin and insulin resistance in Alzheimer’s disease. Int J Mol Sci2021; 22: 9987.
53.
GraySMAylorKWBarrettEJ. Unravelling the regulation of insulin transport across the brain endothelial cell. Diabetologia2017; 60: 1512–1521.
54.
SpielmanLJBahniwalMLittleJP, et al.Insulin modulates in vitro secretion of cytokines and cytotoxins by human glial cells. Curr Alzheimer Res2015; 12: 684–693.
55.
AdzovicLLynnAED’AngeloHM, et al.Erratum to: insulin improves memory and reduces chronic neuroinflammation in the hippocampus of young but not aged brains. J Neuroinflammation2015; 12: 142.
56.
HuYKWangXLiL, et al.MicroRNA-98 induces an Alzheimer’s disease-like disturbance by targeting insulin-like growth factor 1. Neurosci Bull2013; 29: 745–751.
57.
XingHGuoSZhangY, et al.Upregulation of microRNA-206 enhances lipopolysaccharide-induced inflammation and release of amyloid-β by targeting insulin-like growth factor 1 in microglia. Mol Med Rep2016; 14: 1357–1364.
58.
GhavamiSShojaeiSYeganehB, et al.Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog Neurobiol2014; 112: 24–49.
59.
BandaruSSLinKRomingSL, et al.Effects of PI3K inhibition and low docosahexaenoic acid on cognition and behavior. Physiol Behav2010; 100: 239–244.
60.
KumarMBansalN. Implications of phosphoinositide 3-kinase-Akt (PI3K-Akt) pathway in the pathogenesis of Alzheimer’s disease. Mol Neurobiol2022; 59: 354–385.
61.
BrownHAThomasPGLindsleyCW. Targeting phospholipase D in cancer, infection and neurodegenerative disorders. Nat Rev Drug Discov2017; 16: 351–367.
62.
JinJKKimNHLeeYJ, et al.Phospholipase D1 is up-regulated in the mitochondrial fraction from the brains of Alzheimer’s disease patients. Neurosci Lett2006; 407: 263–267.
63.
CaiDNetzerWJZhongM, et al.Presenilin-1 uses phospholipase D1 as a negative regulator of beta-amyloid formation. Proc Natl Acad Sci U S A2006; 103: 941–1946.
64.
JinJKAhnBHNaYJ, et al.Phospholipase D1 is associated with amyloid precursor protein in Alzheimer's disease. Neurobiol Aging2007; 28: 1015–1027.
65.
OliveiraTGChanRBTianH, et al.Phospholipase d2 ablation ameliorates Alzheimer’s disease-linked synaptic dysfunction and cognitive deficits. J Neurosci2010; 30: 16419–16428.
66.
NackenoffAGHohmanTJNeunerSM, et al.PLD3 Is a neuronal lysosomal phospholipase D associated with β-amyloid plaques and cognitive function in Alzheimer’s disease. PLoS Genet2021; 17: e1009406.
67.
LiuGWanQLiJ, et al.Silencing miR-125b-5p attenuates inflammatory response and apoptosis inhibition in mycobacterium tuberculosis-infected human macrophages by targeting DNA damage-regulated autophagy modulator 2 (DRAM2). Cell Cycle2020; 19: 3182–3194.
68.
CaoWQianGLuoW, et al.miR-125b is downregulated in systemic lupus erythematosus patients and inhibits autophagy by targeting UVRAG. Biomed Pharmacother2018; 99: 791–797.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
